nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

22.11.2017 | Basic Science

Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits

verfasst von: Sonia Labrador Velandia, Salvatore Di Lauro, Maria Luz Alonso-Alonso, Soraya Tabera Bartolomé, Girish Kumar Srivastava, José Carlos Pastor, Ivan Fernandez-Bueno

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the feasibility, safety, and biocompatibility of intravitreal injection of human mesenchymal stem cells (MSCs) in immunocompetent pigmented rabbits.

Materials and methods

Thirty-two pigmented rabbits (24 females, 8 males; Chinchilla-New Zealand White) were divided into 8 groups of 4 animals. Commercially prepared human MSCs were injected (0.05 ml) into the post-lens vitreous of the right eyes. Groups 1 and 4 received isotonic medium (Ringer lactate-based), groups 2, 5, 7, and 8 received a low dose of 15 × 10⁶ cells/ml. Groups 3 and 6 received a high dose of 30 × 10⁶ cells/ml. Clinical signs were evaluated and scored before MSCs injection and weekly for 2 or 6 weeks. Animals were sacrificed at 2 or 6 weeks after injection. Eyes, liver, spleen, and gonads were assessed by histology and by fluorescent in situ hybridization to evaluate survival and extraocular migration of MSCs.

Results

There were no relevant clinical findings between control and MSC-injected rabbit eyes at any time point. There were also no relevant histological findings between control and MSC-injected rabbits related to ocular, liver, spleen, or gonad tissues modifications. MSCs survived intravitreally for at least 2 weeks after injection. Extraocular migration of MSCs was not detected.

Conclusions

MSCs are safe and well-tolerated when administered intravitreally at a dose of 15 × 10⁶ cells/ml in pigmented rabbits. These findings enable future research to explore the intravitreal use of commercially prepared allogenic human MSCs in clinical trials of retinal diseases.

Mariotti SP (2010) Global data on visual impairments 2010. World Health Organization, http://www.who.int/blindness/GLOBALDATAFINALforweb.pdf, pp. 17. Accessed Jul 2016

Hayreh SS, Jonas JB, Zimmerman MB (2007) Nonarteritic anterior ischemic optic neuropathy and tobacco smoking. Ophthalmology 114:804–809. https://doi.org/10.1016/j.ophtha.2006.07.062 CrossRefPubMed

Hayreh SS, Zimmerman MB (2007) Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 245:1107–1121. https://doi.org/10.1007/s00417-006-0494-0 CrossRefPubMed

Kupersmith MJ, Frohman L, Sanderson M, Jacobs J, Hirschfeld J, Ku C, Warren FA (1997) Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol 17:250–253CrossRefPubMed

Beck RW, Hayreh SS, Podhajsky PA, Tan ES, Moke PS (1997) Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 123:212–217CrossRefPubMed

Group IONDTR (2000) Ischemic optic neuropathy decompression trial: twenty-four-month update. Arch Ophthalmol 118:793–798CrossRef

Hayreh SS, Zimmerman MB (2008) Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246:1029–1046. https://doi.org/10.1007/s00417-008-0805-8 CrossRefPubMedPubMedCentral

Beck RW (2000) Does Levodopa improve visual function in NAION? Ophthalmology 107: 1431-1434; discusson 1435-1438

Bernstein SL, Mehrabyan Z, Guo Y, Moianie N (2007) Estrogen is not neuroprotective in a rodent model of optic nerve stroke. Mol Vis 13:1920–1925PubMedPubMedCentral

10.

Modarres M, Falavarjani KG, Nazari H, Sanjari MS, Aghamohammadi F, Homaii M, Samiy N (2011) Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 95:992–995. https://doi.org/10.1136/bjo.2010.191627 CrossRefPubMed

11.

Wilhelm B, Ludtke H, Wilhelm H, Group BS (2006) Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 244:551–558. https://doi.org/10.1007/s00417-005-0102-8 CrossRef

12.

Pece A, Querques G, Quinto A, Isola V (2010) Intravitreal ranibizumab injection for nonarteritic ischemic optic neuropathy. J Ocul Pharmacol Ther 26:523–527. https://doi.org/10.1089/jop.2010.0053 CrossRefPubMed

13.

Lamba DA, Karl MO, Reh TA (2009) Strategies for retinal repair: cell replacement and regeneration. Prog Brain Res 175:23–31. https://doi.org/10.1016/S0079-6123(09)17502-7 CrossRefPubMed

14.

Abdallah BM, Kassem M (2008) Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther 15:109–116. https://doi.org/10.1038/sj.gt.3303067 CrossRefPubMed

15.

Phinney DG, Isakova I (2005) Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des 11:1255–1265CrossRefPubMed

16.

Bull ND, Martin KR (2009) Using stem cells to mend the retina in ocular disease. Regen Med 4:855–864. https://doi.org/10.2217/rme.09.59 CrossRefPubMed

17.

Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12:87–117. https://doi.org/10.1146/annurev-bioeng-070909-105309 CrossRefPubMedPubMedCentral

18.

Xu W, Xu GX (2011) Mesenchymal stem cells for retinal diseases. Int J Ophthalmol 4:413–421. https://doi.org/10.3980/j.issn.2222-3959.2011.04.19 PubMedPubMedCentral

19.

McLaren A (2001) Ethical and social considerations of stem cell research. Nature 414:129–131. https://doi.org/10.1038/35102194 CrossRefPubMed

20.

Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499–3506. https://doi.org/10.1182/blood-2007-02-069716 CrossRefPubMed

21.

Vega A, Martin-Ferrero MA, Del Canto F, Alberca M, Garcia V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M, Sanchez A, Garcia-Sancho J (2015) Treatment of knee osteoarthritis with Allogeneic bone marrow Mesenchymal stem cells: a randomized controlled trial. Transplantation 99:1681–1690. https://doi.org/10.1097/TP.0000000000000678 CrossRefPubMed

22.

Seo JH, Cho SR (2012) Neurorestoration induced by mesenchymal stem cells: potential therapeutic mechanisms for clinical trials. Yonsei Med J 53:1059–1067. https://doi.org/10.3349/ymj.2012.53.6.1059 CrossRefPubMedPubMedCentral

23.

Labouyrie E, Dubus P, Groppi A, Mahon FX, Ferrer J, Parrens M, Reiffers J, de Mascarel A, Merlio JP (1999) Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol 154:405–415. https://doi.org/10.1016/S0002-9440(10)65287-X CrossRefPubMedPubMedCentral

24.

Lin N, Hu K, Chen S, Xie S, Tang Z, Lin J, Xu R (2009) Nerve growth factor-mediated paracrine regulation of hepatic stellate cells by multipotent mesenchymal stromal cells. Life Sci 85:291–295. https://doi.org/10.1016/j.lfs.2009.06.007 CrossRefPubMed

25.

Li N, Li XR, Yuan JQ (2009) Effects of bone-marrow mesenchymal stem cells transplanted into vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp Ophthalmol 247:503–514. https://doi.org/10.1007/s00417-008-1009-y CrossRefPubMed

26.

Levkovitch-Verbin H, Sadan O, Vander S, Rosner M, Barhum Y, Melamed E, Offen D, Melamed S (2010) Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci 51:6394–6400. https://doi.org/10.1167/iovs.09-4310 CrossRefPubMed

27.

Kaplan HJ, Chiang CW, Chen J, Song SK (2010) Vitreous volume of the mouse measured by quantitative high-resolution MRI. Invest Ophthalmol Vis Sci 51:4414–4414

28.

Hackett R (1991) Eye irritation. In: Marzulli F, Maibach H (eds) Advances in modern toxicology: Dermatoxicology. Hemisphere Publishing Corporation, Washington, DC, pp 749–815

29.

Makki JS (2016) Diagnostic implication and clinical relevance of ancillary techniques in clinical pathology practice. Clin Med Insights Pathol 9:5–11. https://doi.org/10.4137/CPath.S32784 CrossRefPubMedPubMedCentral

30.

Ramirez BE, Sanchez A, Herreras JM, Fernandez I, Garcia-Sancho J, Nieto-Miguel T, Calonge M (2015) Stem cell therapy for corneal epithelium regeneration following good manufacturing and clinical procedures. Biomed Res Int 2015:408495. https://doi.org/10.1155/2015/408495 CrossRefPubMedPubMedCentral

31.

Del Amo EM, Urtti A (2015) Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res 137:111–124. https://doi.org/10.1016/j.exer.2015.05.003 CrossRefPubMed

32.

Bernstein SL, Johnson MA, Miller NR (2011) Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Prog Retin Eye Res 30:167–187. https://doi.org/10.1016/j.preteyeres.2011.02.003 CrossRefPubMedPubMedCentral

33.

Griffin G, Clark JM, Zurlo J, Ritskes-Hoitinga M (2014) Scientific uses of animals: harm-benefit analysis and complementary approaches to implementing the three Rs. Rev Sci Tech 33:265–272CrossRefPubMed

34.

Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R (2011) Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina 31:1207–1214. https://doi.org/10.1097/IAE.0b013e3181f9c242 CrossRefPubMed

35.

Jonas JB, Witzens-Harig M, Arseniev L, Ho AD (2008) Intravitreal autologous bone marrow-derived mononuclear cell transplantation: a feasibility report. Acta Ophthalmol 86:225–226. https://doi.org/10.1111/j.1600-0420.2007.00987.x CrossRefPubMed

36.

Lee JW, Park H, Choi JH, Lee HJ, Moon SW, Kang JH, Kim YG (2016) Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol 16:69. https://doi.org/10.1186/s12886-016-0255-8 CrossRefPubMedPubMedCentral

37.

Ge J, Guo L, Wang S, Zhang Y, Cai T, Zhao RC, Wu Y (2014) The size of mesenchymal stem cells is a significant cause of vascular obstructions and stroke. Stem Cell Rev 10:295–303. https://doi.org/10.1007/s12015-013-9492-x CrossRefPubMed

38.

Nishihara H (1989) Studies on the ultrastructure of the inner limiting membrane of the retina. I. Surface replication study on the inner limiting membrane of the retina. Nippon Ganka Gakkai Zasshi 93:429–438PubMed

39.

Shen J, Durairaj C, Lin T, Liu Y, Burke J (2014) Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown. Invest Ophthalmol Vis Sci 55:1056–1066. https://doi.org/10.1167/iovs.13-13650 CrossRefPubMed

40.

Zhang C, Guo Y, Slater BJ, Miller NR, Bernstein SL (2010) Axonal degeneration, regeneration and ganglion cell death in a rodent model of anterior ischemic optic neuropathy (rAION). Exp Eye Res 91:286–292. https://doi.org/10.1016/j.exer.2010.05.021 CrossRefPubMedPubMedCentral

Titel: Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits
verfasst von: Sonia Labrador Velandia
Salvatore Di Lauro
Maria Luz Alonso-Alonso
Soraya Tabera Bartolomé
Girish Kumar Srivastava
José Carlos Pastor
Ivan Fernandez-Bueno
Publikationsdatum: 22.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2018
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3842-3

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits

Abstract

Purpose

Materials and methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Non-invasive detection of HPV DNA in exfoliative samples from ophthalmic pterygium: a feasibility study

Laser photocoagulation as treatment of non-exudative age-related macular degeneration: state-of-the-art and future perspectives

In vivo confocal laser microscopy of morphologic changes after small incision lenticule extraction with accelerated cross-linking (SMILE Xtra) in patients with thin corneas and high myopia

Checkpoint inhibitor-induced uveitis: a case series

Impact of herpetic stromal immune keratitis in corneal biomechanics and innervation

OCT-based deep learning algorithm for the evaluation of treatment indication with anti-vascular endothelial growth factor medications

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde